Prescription drug costs are a significant burden on cancer patients and survivors, sometimes even leading patients to miss or delay taking prescribed medications. The latest Survivor Views survey explores the role copay assistance programs can play in reducing this burden, and also addresses patient navigation and digital therapeutics.
Recommendations for FDA's Office of Minority Health and Health Equity (OMHHE)
In response to a request from FDA, ACS CAN has provided recommendations for areas of focus for the Office of Minority Health and Health Equity (OMHHE). Recommendations include assessing the applicability of drug "snapshot" data, evaluating the appropriateness of aggregating racial groups for analysis, and examination of drug classes where differences in metabolism, safety or efficacy are likely to be seen.